A Questionnaire Survey on the Clinical Use of Pirfenidone Capsules Among Physicians in Henan Province
ZANG Kaixuan
WANG Zheng
CHEN Shanshan
ZHANG Xiaoju
ZHANG Guojun
YU Xueqing
MAO Yimin
ZHANG Yijie
Abstract：Objective To investigate the attitude and knowledge of physicians in Henan Province in prescribing pirfenidone capsules.Methods From June 11 to 14,2023,an electronic questionnaire was developed and used in the on-line investigation with doctors from the internal or respiratory departments of second-and third-level hospitals in Henan Province.Results A total of 333 valid questionnaires were collected.The primary indications of pirfenidone capsules include idiopathic pulmonary fibrosis(IPF).With regard to the use of pirfenidone capsules in IPF,progressive pulmonary fibrosis,fibrotic interstitial lung disease,connective tissue disease-associated interstitial lung disease(CTD-ILD),the average score of consent was 4.55,4.25,4.17,3.82.About the proportion of patients with IPF using antifibrotic therapy,the proportion choosing 0-30％,30％-50％,50％-70％,and more than 70％was 36.0％,19.2％,17.4％,and 27.3％,respectively.It was found that 69.4％believed that the majority of patients can tolerate the adverse reactions of pirfenidone capsules.Conclusion Considerable heterogeneity lies in the indications,methods,and adverse reaction management of pirfenidone capsules in physicians,and consensus guidelines are in need for further standardization of its use.
Keywords：interstitial lung diseaseidiopathic pulmonary fibrosispirfenidone capsuleindicationadverse effect
Publication Date：2025-11-28
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：6( 4052-4057 )